IN8bio shares surge 12.90% after-hours on Q4 2025 financial results and durable glioblastoma survival improvements.

IN8bio surged 12.90% in after-hours trading following a news report that director Jeremy Graff acquired 2,500 company shares. The insider purchase, disclosed on September 20 at 8:06 PM, signaled confidence in the firm’s prospects amid ongoing clinical advancements, including durable survival improvements in glioblastoma trials and a robust pipeline. While the stock had faced volatility earlier in the year due to mixed preclinical data and orphan drug designations, the insider buying in the immediate after-hours session directly aligned with the price surge. Other recent events, such as conference participation and patent grants, were older and less likely to drive the specific after-hours movement.